Streetwise Biotechnology / Pharmaceuticals Articles


Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

  ()
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. read more >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. read more >

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status. read more >

Biotech Announces Positive Topline Data in Tourette Syndrome

Research Report
  ()
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. read more >

CMS Unexpectedly Issues Product Billing Code to Biotech

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm. read more >

RNAi Therapeutics Developer Reports Positive Amyloidosis Data

Research Report
  ()
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. read more >

Biotech Delivers 'Excellent' Phase 2 Data

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. read more >

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

Research Report
  ()
The company performed strongly in the U.S. and the Asia Pacific region. read more >

Regrouped Biotech's Stock Price Could See Fifteenfold Increase

Research Report
  ()
A recent conference call provided clinical and financial updates. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >
Management Q&A: View from the Top

Biotech Advances Treatments for Liver Disease, Pain, Mental Illness

Managment Q&A: View from the Top
  ()
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018. read more >

Two Biotechs Earn Analyst's Top Pick Ranking

  ()
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well. read more >

Price Target on Biotech Is a 700% Potential Increase

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. read more >

Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

Research Report
  ()
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. read more >

Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3

Research Report
  ()
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. read more >

Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside

Research Report
  ()
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. read more >

Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet

Research Report
  ()
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. read more >

Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

Research Report
  ()
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential. read more >

Fund Manager Names Three Small-Caps with Strong Growth Profiles

  ()
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects. read more >

Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple

  ()
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." read more >

Biotech with Tenbagger Potential Signs Deal with Chinese Firm

Research Report
  ()
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans. read more >

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle

Contributed Opinion
  ()
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. read more >

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Research Report
  ()
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. read more >

Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List

  ()
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. read more >

Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis'

Research Report
  ()
H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer. read more >
Showing Results: 26 to 50 of 53 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research